ArticleScientific reports2025
Pan-cancer analysis reveals ASCC family promotes the cancer progression of lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity.The journal of pathology. Clinical research · 2026Article
- ASCC3 promotes chemosensitivity in colorectal cancer cells.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ASC-1 complex, consisting of TRIP4, ASCC1, ASCC2, and ASCC3, plays a pivotal role in regulating nuclear receptors and transcription factors that influence immunity, cellular proliferation, and apoptosis, and a multiomic analysis of ASCC1/2/3 was therefore performed to investigate its potential role on a pan-cancer scale. Although it has been implicated in DNA repair mechanisms and neurodegenerative diseases, its specific function within cancer biology remains poorly understood. This study conducted a pan-cancer analysis of ASCC1/2/3's roles in the tumorigenesis process and explored their regulatory effects on lung adenocarcinoma. We conducted a comprehensive analysis of 10,967 tumor samples across 30 distinct cancer types. It was found that alterations in ASCC1/2/3 occurred in 754 cases (7% of the patients analyzed), with ASCC3 being the most frequently altered at 4%. Furthermore, elevated expression levels of ASCC1/2/3 were observed in the majority of cancer types examined. Notably, the expression levels of ASCC1 and ASCC3 demonstrated a correlation with CD4-positive T cell infiltration. In vitro experiments demonstrated that the ASCC family effectively inhibited tumor proliferation, migration, and invasion in lung adenocarcinoma cell line. Our findings indicate a significant association between the ASCC family and tumors while providing a foundation for further investigation into its role in cancer biology and potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.